e-learning
resources
Virtual 2021
07.09.2021
Pulmonary hypertension in the COVID-19 pandemic and beyond
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Spectrum of interstitial lung diseases (ILDs) and associated prevalence of pulmonary hypertension
R. Tyagi (Lucknow (UP), India), S. Kant (Lucknow (UP), India), A. Wakhlu (Lucknow (UP), India), A. Parihar (Lucknow (UP), India), A. Pradhan (Lucknow (UP), India), R. Jaiswal (Lucknow (UP), India)
Source:
Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond
Session:
Pulmonary hypertension in the COVID-19 pandemic and beyond
Session type:
E-poster
Number:
3597
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Tyagi (Lucknow (UP), India), S. Kant (Lucknow (UP), India), A. Wakhlu (Lucknow (UP), India), A. Parihar (Lucknow (UP), India), A. Pradhan (Lucknow (UP), India), R. Jaiswal (Lucknow (UP), India). Spectrum of interstitial lung diseases (ILDs) and associated prevalence of pulmonary hypertension. 3597
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Optimizing invasive ventilation for SMA type 1 children who are receiving the gene therapy
Pulmonary sarcoidosis
Definition and history of sarcoidosis
Related content which might interest you:
Bosentan treatment in pulmonary arterial hypertension (PAH) associated with interstitial lung diseases (ILDs)
Source: Eur Respir J 2006; 28: Suppl. 50, 426s
Year: 2006
Comparison of pulmonary hypertension (PH) associated to chronic lung disease to other PH groups
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016
Prevalence and incidence of interstitial lung diseases (ILDs) in a French multi-ethnic county
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype
Source: Eur Respir Rev, 27 (150) 180077; 10.1183/16000617.0077-2018
Year: 2018
Pulmonary hypertension in different interstitial lung diseases
Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Year: 2012
Comorbidities in patients with the combined pulmonary fibrosis and emphysema syndrome (CPFE)
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
Pulmonary hypertension in interstitial lung diseases
Source: Annual Congress 2009 - Sarcoidosis and profiles of other diffuse parenchymal lung disease
Year: 2009
Biomarkers in pulmonary hypertension associated to interstitial lung disease
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
Scleroderma lung disease: Detection of pulmonary hypertension using pulmonary function tests is problematic in patients with emphysema
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Determination of pulmonary hypertension degree in patients with interstitial lung diseases
Source: Annual Congress 2010 - Different patterns of interstitial lung disease
Year: 2010
Interstital lung diseases: update 2005
Source: Annual Congress 2005 - Clinical year in review
Year: 2005
Study of factors affecting mortality in ILD cases over 2 years
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Seasonal epidemiology and clinical manifestations of interstitial lung diseases (ILD) as an important criterion for differential diagnosis viral pneumonia with pulmonary arterial hypertention (PAH) associated with severe COVID-19.
Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends
Year: 2021
Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Baseline characteristics and survival of patients with pulmonary hypertension in interstitial lung disease in the “HYPID” study
Source: Annual Congress 2013 –Pulmonary circulation: clinical physiology
Year: 2013
Interstitial lung diseases in childhood
Source: ISSN=1025-448x, ISBN=1-904097-22-7, page=213
Year: 2002
Pulmonary hypertension in patients with interstitial lung disease
Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases
Year: 2011
Using the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Rare interstitial lung diseases of environmental origin
Source: Eur Respir Mon 2011; 54: 301-316
Year: 2011
Pulmonary hypertension in interstitial lung disease
Source: Eur Respir J 2008; 31: 1357-1367
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept